TESARO (NASDAQ:TSRO)‘s stock had its “hold” rating reiterated by research analysts at Piper Jaffray Companies in a research report issued on Thursday. They presently have a $65.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target points to a potential upside of 2.36% from the company’s previous close.
A number of other research analysts have also weighed in on the company. Credit Suisse Group reissued an “outperform” rating and issued a $150.00 price objective (down from $190.00) on shares of TESARO in a report on Thursday. Morgan Stanley cut their price objective on TESARO from $165.00 to $156.00 and set an “overweight” rating on the stock in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $158.00 target price on shares of TESARO in a research note on Friday, January 12th. Zacks Investment Research downgraded TESARO from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Finally, Cowen lowered their target price on TESARO from $125.00 to $80.00 and set a “market perform” rating on the stock in a research note on Tuesday, January 2nd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $149.97.
Shares of TESARO (NASDAQ TSRO) traded up $1.64 during mid-day trading on Thursday, hitting $63.50. The stock had a trading volume of 3,030,000 shares, compared to its average volume of 984,761. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $3,450.00, a price-to-earnings ratio of -7.53 and a beta of 1.51. TESARO has a fifty-two week low of $59.77 and a fifty-two week high of $192.94.
In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 40.50% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Exane Derivatives purchased a new position in TESARO in the third quarter valued at $106,000. Nordea Investment Management AB purchased a new position in TESARO in the second quarter valued at $167,000. Oppenheimer Asset Management Inc. boosted its holdings in TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,430 shares during the period. Toronto Dominion Bank boosted its holdings in TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,130 shares during the period. Finally, Fox Run Management L.L.C. purchased a new position in TESARO in the fourth quarter valued at $218,000.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/18/piper-jaffray-companies-reiterates-hold-rating-for-tesaro-tsro.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.